Compare EICA & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EICA | AGMB |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | Belgium |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 774.9M |
| IPO Year | 2021 | N/A |
| Metric | EICA | AGMB |
|---|---|---|
| Price | $24.71 | $13.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 3.5K | ★ 125.5K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.00 | $13.50 |
| 52 Week High | $24.98 | $17.45 |
| Indicator | EICA | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 31.18 |
| Support Level | $24.70 | N/A |
| Resistance Level | $24.73 | $16.82 |
| Average True Range (ATR) | 0.09 | 1.30 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 3.61 | 10.11 |
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.